Return to the full list of Biomarkers
Eye Movement Recording (MOMAD)
Method of Measurement (Pre-analytical Tools)
Optical
Biomarker Measured
Eye movement
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
Validate eye movement recording as an early differential diagnostic tool, in order to discriminate as early as possible between neurodegenerative dementias of Alzheimer type and depressive pseudodementias (DPD).
Target Population/ Population Being Studied
Patients suffering of AD and DPD and healthy persons
Length of Current Trial
36 months
Number of Trial Participants
288
Estimated Trial Completion
July 2018 clinical trials says it is active, but date has passed
What is Required from Patients
noninvasive eye tracking test, in clinic visit
What is Required from the Health System
eye tracking device
Sponsor
Centre Hospitalier Universitaire de Besancon; Laboratoire de psychologie EA 3188; Centre Hospitalier Universitaire Dijon; Centre Hospitalier de Novillars
“Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression (MOMAD).” ClinicalTrials.gov. October, 10, 2019.
https://clinicaltrials.gov/ct2/show/NCT01434940